The relationship between CD4 cell count nadirs and the toxicity profiles of antiretroviral regimens

Antiviral Therapy

Volumn 10, Issue 3, 2005, Pages 459-467

  Smith, Colette J ^a   Sabin, Caroline A ^a   Lampe, Fiona C ^a   Shah, Sapna ^a,b   Tyrer, Mervyn ^b   Youle, Mike S ^b   Cropley, Ian ^b   Johnson, Margaret A ^b   Phillips, Andrew N ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; HEMOGLOBIN; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TRIACYLGLYCEROL; ZIDOVUDINE;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMOGLOBIN DETERMINATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; KIDNEY DYSFUNCTION; LIPODYSTROPHY; LIVER TOXICITY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALAISE; MALE; MYOSITIS; NAUSEA; NEUROTOXICITY; PANCREATITIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; TRIACYLGLYCEROL BLOOD LEVEL; UNITED KINGDOM; BLOOD; CD4 LYMPHOCYTE COUNT;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; MALE;

EID: 20444454616     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, Knysz B, Dietrich M, Phillips AN & Lundgren JD; EuroSIDA study group. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362:22-29.
2. Egger M, Hirschel B, Francioli P, Sudre P, Wirz M, Flepp M, Rickenbach M, Malinverni R, Vernazza P & Battegay M. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. British Medical Journal 1997; 315:1194-1199.
3. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ & Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine 1998; 338:853-860.
4. Powderly WG. Long-term exposure to lifelong therapies. Journal of Acquired Immune Deficiency Syndromes 2002; 29:S28-S40.
5. Arenas-Pinto A, Grant AD, Edwards S & Weller IVD. Lactic acidosis in HIV infected patients: a systematic review of published cases. Sexually Transmitted Infections 2003; 79:344.
6. Mondy K, Yarasheski K, Powderly WG, Whyte M, Claxton S, DeMarco D, Hoffmann M & Tebas P. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clinical Infectious Diseases 2003; 36:482-490.
7. Carr A & Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356:1423-1430.
8. Hewitt RG. Abacavir hypersensitivity reaction. Clinical Infectious Diseases 2002; 15:1137-1142.
9. Fagot JP, Mockenhaupt M, Bouwes-Bavinck JN, Naldi L, Viboud C & Roujeau JC. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS 2001; 15:1848.
10. Sundar K. Zidovudine-induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: report of two patients and review of the literature. Critical Care Medicine 1997; 8:1425-1430.
11. Gallant JE. Initial therapy of HIV infection. Journal of Clinical Virology 2002; 25:317-333.
12. Lichtenstein KA, Armon C, Baron A, Moorman AC, Wood KC & Holmberg SD; HIV Outpatient Study Investigators. Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV Outpatient Study Cohort. Clinical Infectious Diseases 2005; 40:148-157.
13. Thiebaut R, Dequae-Merchadou L, Ekouevi DK, Mercie P, Malvy D, Neau D & Dabis F; Groupe d'Epidemiologie Clinique du SIDA en Aquitane (GECSA). Incidence and risk factors of severe hypertriglyceridaemia in the era of highly active antiretroviral therapy: the Aquitaine Cohort, France, 1996-99. HIV Medicine 2001; 2:84-88.
14. Lucas GM, Chaisson RE & Moore RD. Highly active anti-retroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Annals of Internal Medicine 1999; 131:81-87.
15. Wit FW, Wood R, Horban A, Beniowski M, Schmidt RE, Gray G, Lazzarin A, Lafeuillade A, Paes D, Carlier H, van Weert L, de Vries C, van Leeuwen R & Lange JM. Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine. AIDS 2001; 15:2423-2429.
16. Bonnet F, Bonarek M, Morlat P, Mercie P, Dupon M, Gemain MC, Malvy D, Bernard N, Pellegrin JL & Beylot J. Risk factors for lactic acidosis in HIV-infected patients treated with nucleoside reverse transcriptase inhibitors: a case control study. Clinical Infectious Diseases 2003; 36:1324-1328.
17. Bonnet F, Saves M, Droz C, Peuchant E, Chene G, Beylot J & Morlat P. Increase of atherogenic plasma profile in HIV-infected patients treated with protease inhibitor-containing regimens. Journal of Acquired Immune Deficiency Syndromes 2000; 25:199-200.
18. Dieleman JP, van Rossum AM, Stricker BC, Sturkenboom MC, de Groot R, Telgt D, Blok WL, Burger DM, Blijenberg BG, Zietse R & Gyssens IC. Persistent leukocyturia and loss of renal function in a prospectively monitored cohort of HIV-infected patients treated with indinavir. Journal of Acquired Immune Deficiency Syndromes 2003; 32:135-142.
19. Heath KV, Hogg R, Singer J, Chan KJ, O'Shaughnessy MV & Montaner JSG. Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based cohort. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology 2002; 30:440-447.
20. Kirk O, Gerstoft J, Pedersen C, Nielsen H, Obel N, Katzenstein TL, Mathiesen L & Lundgren JD. Low body weight and type of protease inhibitor predict discontinuation and treatment-limiting adverse drug reactions among HIV-infected patients starting a protease inhibitor regimen: consistent results from a randomised trial and an observational cohort. HIV Medicine 2001; 2:43-51.
21. Herman JS, Ives NJ, Nelson M, Gazzard BG & Easterbrook PJ. Incidence and risk factors for the development of indinavir-associated renal complications. Journal of Antimicrobial Chemotherapy 2001; 48:355-360.
22. Sabin CA, Lampe FC, Chaloner C, Madge SJ, Lipman MC, Youle M, Phillips AN & Johnson MA. An audit of anti-retroviral treatment use in HIV-infected patients in a London clinic. HIV Medicine 2003; 4:87-93.
23. Fine JP & Gray RJ. A proportional hazards model for the subdistribution of a competing risk. Journal of the American Statistical Association 1999; 94:496-509.
24. Moyle G, Sawyer W, Law M, Amin J & Hill A. Changes in hematologic parameters and efficacy of thymidine analogue-based, highly active antiretroviral therapy: a meta-analysis of six prospective, randomized, comparative studies. Clinical Therapeutics 2004; 26:92-97.
25. Puoti M, Torti C, Ripamonti D, Castelli F, Zaltron S, Zanini B, Spinetti A, Putzolu V, Casari S, Tomasoni L, Quiros-Roldan E, Favret M, Berchich L, Grigolato P, Callea F & Carosi G; HIV-HCV Co-Infection Study Group. Severe hepatotoxicity during combination antiretroviral therapy treatment: incidence, liver histology, and outcome. Journal of Acquired Immune Deficiency Syndromes 2003; 32:259-267.
26. Qurishi N, Kreuzberg C, Luchters G, Effenberger W, Kupfer B, Sauerbruch T, Rockstroh JK & Spengler U. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362:1708-1713.
27. Dore G. Antiretroviral therapy-related hepatotoxicity: predictors and clinical management. Journal of HIV Therapy 2003; 8:96-100.
28. Martinez E, Blanco JL, Arnaiz JA, Perez-Cuevas JB, Mocroft A, Cruceta A, Marcos MA, Milinkovic A, Garcia-Viejo MA, Mallolas J, Carne X, Phillips A & Gatell JM. Hepatotoxicity in HIV-1 infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001; 15:1261-1268.
29. Lichtenstein KA, Ward DJ, Moorman AC, Delaney KM, Young B, Palella FJ Jr, Rhodes PH, Wood KC & Holmberg SD; HIV Outpatient Study Investigators. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 2001; 15:1389-1398.
30. Lichtenstein KA, Delaney KM, Armon C, Ward DJ, Moorman AC, Wood KC & Holmberg SD; HIV Outpatient Study Investigators. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1 infected patients. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology 2003; 32:48-56.